This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.
18, 2025 About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, kidneydisease, type 2 diabetes and obesity.[1] DALLAS, Feb. 1] This cluster of chronic health conditions is called.
The first quarter of 2025 saw approvals in diabetes, depression, kidneydisease, and pain, among others. Read more about high-impact approvals of Q1 now.
tim.hodson Wed, 04/09/2025 - 14:38 April 9, 2025 Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced March 17, 2025 ), has now approved the updated label for Tryvio(aprocitentan). Hypertension.
tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidneydisease (CKD) and other diseases, hasannounced that the U.S.
Nature Reviews Cardiology, Published online: 26 March 2025; doi:10.1038/s41569-025-01149-8 A study published in Nature has identified two transmembrane G protein-coupled receptors that mediate extracellular-to-intracellular ceramide signalling and shows that blocking these receptors alleviates the atherosclerosis that is induced by a high-fat diet (..)
This exciting overview highlights the top 10 AI-powered cardiometabolic startups poised to make significant impacts in 2025. Eko : AI-powered heart sound and EKG sensors paired with FDA-approved software for heart disease monitoring. Viz.ai : Uses AI to enhance care coordination and improve outcomes in cardiovascular care.
Stroke, Volume 56, Issue Suppl_1 , Page ADP60-ADP60, February 1, 2025. Background:Chronic kidneydisease (CKD) has emerged as an independent risk factor for cerebral microhemorrhages (CMH). adenine diet to induce CKD, or angiotensin II (ATII) via subcutaneous osmotic pumps to induce HTN and compared with control mice.
Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidneydisease, or heart failure, as well as among adults with few cardiovascular risk factors.
Stroke, Volume 56, Issue Suppl_1 , Page AWP171-AWP171, February 1, 2025. Background:The prevalence of renal disease is increasing in the U.S. For the analysis, subjects were categorized as advanced chronic kidneydisease (CKD, CrCl 15-30) and end stage renal disease (ESRD, CrCl<15).Results:Of
On-demand access is available now and will remain open until December 2025. If you attended the 19th Annual Cardiometabolic Health Congress (CMHC), please reach out to info@cardiometabolichealth.org and we will provide you with a complimentary access code to this activity. When Will It Be Available?
Publication date: Available online 20 February 2025 Source: The American Journal of Cardiology Author(s): Min Choon Tan, Aravinthan Vignarajah, Tanusha Winson, Yong Hao Yeo, Qi Xuan Ang, Ramzi Ibrahim, Justin Z.
Publication date: Available online 7 February 2025 Source: The American Journal of Cardiology Author(s): Nicholas Fialka, Ryaan EL-Andari, Jimmy Kang, Yongzhe Hong, Finlay A. McAlister, Jayan Nagendran, Jeevan Nagendran
Hypertension, Volume 82, Issue 1 , Page 14-25, January 1, 2025. Earlier detection of albuminuria and podocyte injury through routine noninvasive diagnostics will also be critical in populations at the highest risk for the development of hypertensive kidneydisease.
Stroke, Volume 56, Issue Suppl_1 , Page AWP294-AWP294, February 1, 2025. Background:Racial disparities have been well described in cardiovascular disease. Patients were categorized into two groups, one with Black or African American and another with White race patients. Both groups were followed for 12 months.
Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Hypertension, diabetes, hyperlipidemia, and chronic kidneydisease are well-known cardiovascular risk factors for ICH. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.
Stroke, Volume 56, Issue Suppl_1 , Page A52-A52, February 1, 2025. Patients were assessed at follow-up periods of 1 month and 1 year. Result:After 1:1 propensity score matching, the study cohort comprised 895 patients receiving GLP-1 RA and 895 patients in the control group.
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25
DALLAS, March 24, 2025 Globally, the rate of death from chronic kidneydisease increased 24% from 1990 to 2021, according to statistics published by the American Heart Association, a global force changing the future of health for all. The rise in.
tim.hodson Wed, 03/26/2025 - 14:25 March 17, 2025 Bayer recently announcedthat the U.S. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidneydisease (CKD). Accessed February 21, 2025. Accessed March 5, 2025. Accessed February 21, 2025. J Card Fail.
Stroke, Volume 56, Issue Suppl_1 , Page ATP294-ATP294, February 1, 2025. Introduction:Chronic kidneydisease (CKD) and ischemic stroke are both associated with significant global disease burdens and share common risk factors. Understanding the impact of CKD on stroke incidence is essential for improving patient outcomes.
milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidneydisease (CKD) as well as hypertension and cardiovascular disease.
Stroke, Volume 56, Issue Suppl_1 , Page ADP47-ADP47, February 1, 2025. Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across t he KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Additional ACC.25
Stroke, Volume 56, Issue Suppl_1 , Page AWP319-AWP319, February 1, 2025. Reliability of self-reported risk factors was high in overweight (F1 0.81) and diabetes (F1 0.71), moderate in hearing impairment (F1 0.59) and hypertension (F1 0.56) and low in hypercholesterolemia (F1 0.49) and kidneydisease (F1 0.25).
Stroke, Volume 56, Issue Suppl_1 , Page AWP289-AWP289, February 1, 2025. Background:The ABCD-GENE score, incorporating age, body mass index, chronic kidneydisease, diabetes, and CYP2C19 genotypes, is a validated risk score that integrates clinical risk factors with genetic information to predict clopidogrel response.
Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages.
Stroke, Volume 56, Issue Suppl_1 , Page AWP184-AWP184, February 1, 2025. Objective:High calcium (Ca), low phosphate(P), and Ca-P product (CPP) levels are associated with cardiovascular disease and coronary artery atherosclerosis in patients with chronic kidneydisease.
Stroke, Volume 56, Issue Suppl_1 , Page AWP301-AWP301, February 1, 2025. VRFs included hypertension, diabetes, kidneydisease, smoking, drug or alcohol abuse, antithrombotic medication use, and sleep apnea. Introduction:While intracranial hemorrhage (ICH) is uncommon in young adults (18-55), its incidence is on the rise.
Stroke, Volume 56, Issue Suppl_1 , Page ATP360-ATP360, February 1, 2025. Only age (point estimate 0.02, p=0.04) and history of chronic kidneydisease (point estimate 7.57, p<0.01) were significantly associated with elevated kynurenine concentrations in all stroke patients while controlling for covariables.
In contrast, nontraditional risk factors, such as blood clots in the veins, migraine with aura, chronic kidneydisease, chronic liver disease or cancer, were more strongly associated with stroke among study participants with a PFO.
Acute hyperkalemia in the emergency department: a summary from a KidneyDisease: Improving Global Outcomes conference. J Emerg Med 2020. == MY Comment , by K EN G RAUER, MD ( 1/29 /2025 ): == Today's case by Dr. McLaren serves as an important reminder of critical pitfalls in the treatment of hyperkalemia. References 1.
Additionally, 10% of the global population suffers from chronic kidneydisease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,
Mechanical complications such as free wall rupture, VSR and papillary muscle rupture is more likely to occur in patients who are older, female, hypertensive, have chronic kidneydisease, and have no prior history of smoking. link] [6] Contemporary Management of Post-MI Ventricular Septal Rupture - American College of Cardiology.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content